ApoVax, Inc., a biotechnology company, developing immunotherapies -- regulating the immune system to fight against diseases. Anchored in work initaited at the University of Louisvillle, products offered by the firm include ApoVax104, a recombinant protein vaccine that combines with antigens, tumors, and infectious disease markers and stimulates an immune response to create a disease-specific vaccine or therapeutic ; and ProtEx, a technology that enables recombinant immunoregulatory proteins to be placed on the surface of cells, tissues, organs, and synthetic surfaces to modulate the immune system. The company's products also include ApoVax104-HPV, a therapeutic vaccine for cervical cancer and human papillomavirus infection in women. In addition, its research programs comprise infectious diseases, autoimmune diseases, and cell/organ transplantation. Formerly known as ApoImmune, Inc., the firm's name was changed to ApoVax, Inc. in 2010.
